Henry Ji

Henry Ji is recorded as Chairman at Scilex Holding Co (SCLX) since September 22, 2023, CEO at Scilex Holding Co (SCLX) and CEO at Semnur Pharmaceuticals, Inc. (SMNR). The newest filing on record that lists Henry Ji as CEO at Scilex Holding Co (SCLX) is dated April 30, 2026. The newest filing on record that lists Henry Ji as CEO at Semnur Pharmaceuticals, Inc. (SMNR) is dated April 30, 2026. Semnur Pharmaceuticals, Inc. reported in an 8-K filed March 17, 2026 that Henry Ji was appointed Chief Executive Officer and President, effective March 13, 2026. Scilex Holding Co reported in an 8-K filed August 21, 2025 that Henry Ji was appointed Chief Executive Officer and President, effective August 17, 2025. Scilex Holding Co reported in an 8-K filed September 22, 2023 that Henry Ji was appointed Executive Chairperson of the Board, effective September 22, 2023. Equibles holds 6 filed executive changes naming Henry Ji; each is listed under recent activity with its source filing. The proxy statement of Scilex Holding Co reports total compensation of $3,069,495 for Henry Ji in fiscal 2025, including a base salary of $1,557,663. Disclosed compensation is on record for 4 fiscal years. Scilex Holding Co is classified in the Drug Manufacturers - General industry within the Healthcare sector. Semnur Pharmaceuticals, Inc. is classified in the Biotechnology industry within the Healthcare sector. Other leadership on record at Scilex Holding Co includes Jaisim Shah (CEO and Board Member), Elizabeth Czerepak (CFO), Stephen Ma (CFO, COO and Board Member) and 7 others.